Login
Super Investors RA CAPITAL MANAGEMENT, L.P.
RC

RA CAPITAL MANAGEMENT, L.P.

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$9.97B
Positions
92
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (54 quarters reported)

$11.5B $696M
Q2 13 Q1 16 Q4 18 Q3 21 Q2 24 Q3 26

$754M in Q2 2013 → $9.97B now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Ascendis Pharma A/s 23.5% Unchanged 10,281,496 $2.34B
PM Parabilis Medicines Inc 9.5% Added 0.8% 29,177,964 $942M
Vaxcyte Inc 6.5% Unchanged 11,474,599 $653M
Rhythm Pharmaceuticals Inc 6.4% Unchanged 6,666,837 $635M
Edgewise Therapeutics Inc 3.4% Unchanged 8,392,730 $341M
Tyra Biosciences Inc 2.7% Unchanged 12,198,625 $267M
Freenome Inc 2.4% New 15,367,270 $242M
Hemab Therapeutics Holdings 2.4% Unchanged 7,808,627 $241M
NP Newamsterdam Pharma Co Nv 2.3% Unchanged 9,550,191 $232M
Septerna Inc 2.2% Trimmed 21% 5,502,858 $215M
Spyglass Pharma Inc 2.1% Unchanged 8,021,117 $209M
Janux Therapeutics Inc 1.9% Unchanged 11,189,693 $193M
Mineralys Therapeutics Inc 1.9% Unchanged 7,692,750 $193M
Disc Medicine Inc 1.6% Unchanged 2,450,221 $160M
Taysha Gene Therapies Inc 1.5% Added 29% 30,435,190 $148M
Bicara Therapeutics Inc 1.4% Unchanged 7,255,993 $135M
Artiva Biotherapeutics Inc 1.3% Added 3.0% 18,489,293 $132M
Xencor Inc 1.3% Unchanged 5,274,274 $132M
Oruka Therapeutics Inc 1.3% Unchanged 1,554,597 $129M
Amylyx Pharmaceuticals Inc 1.2% New 4,279,341 $125M
Climb Bio Inc 1.2% Trimmed 10% 10,130,130 $116M
AS Abivax Sa-adr 1.0% Trimmed 9.1% 1,030,058 $102M
Wave Life Sciences Inc 1.0% New 26,975,505 $99.8M
LB Latigo Biotherapeutics Inc 0.9% New 5,302,933 $88.6M
Solid Biosciences Inc 0.9% Unchanged 12,036,126 $87M
Vor Biopharma Inc 0.9% Added 87% 4,503,882 $85.9M
Lb Pharmaceuticals Inc 0.9% Unchanged 2,208,604 $84.8M
Gh Research PLC 0.8% Trimmed 53% 3,609,007 $84.7M
Obsidian Therapeutics Inc 0.8% New 5,957,103 $81.8M
ZL Zai Lab Ltd-adr 0.7% Trimmed 51% 2,815,543 $74.2M
4M 4d Molecular Therapeutics In 0.7% Unchanged 5,049,779 $72.3M
Aclaris Therapeutics Inc 0.7% Unchanged 12,723,026 $66.9M
Sana Biotechnology Inc 0.5% Unchanged 18,750,000 $54.7M
Monopar Therapeutics Inc 0.5% Unchanged 667,207 $53.2M
Geron Corp 0.5% Trimmed 0.1% 42,754,145 $52.6M
Damora Therapeutics Inc 0.5% New 2,399,702 $51.1M
Pepgen Inc 0.5% Unchanged 20,064,545 $48.6M
Ars Pharmaceuticals Inc 0.5% Unchanged 10,860,977 $46.8M
Acumen Pharmaceuticals Inc 0.5% Unchanged 20,992,669 $46.6M
DT Dbv Technologies Sa-spon ADR 0.4% New 3,657,644 $43M
Agenus Inc 0.4% New 4,122,000 $40.9M
Rezolute Inc 0.4% Unchanged 9,445,039 $39.1M
Sionna Therapeutics Inc 0.3% Trimmed 35% 6,456,234 $34M
ST Scribe Therapeutics Inc 0.3% New 1,802,178 $33.2M
Century Therapeutics Inc 0.3% Unchanged 17,754,430 $30.4M
Evommune Inc 0.3% Unchanged 3,494,638 $28.9M
Korsana Biosciences Inc 0.3% New 892,743 $28.6M
Capricor Therapeutics Inc 0.3% Added 100% 3,014,183 $28.5M
Nkarta Inc 0.3% Unchanged 10,805,129 $28.3M
C4 Therapeutics Inc 0.3% Added 2.4% 8,194,779 $27.3M
Jade Biosciences Inc 0.3% Trimmed 50% 1,835,542 $25.8M
Prelude Therapeutics Inc 0.3% Unchanged 6,475,882 $25.3M
Acrivon Therapeutics Inc 0.3% Unchanged 12,229,396 $25.1M
Assembly Biosciences Inc 0.2% Unchanged 1,020,410 $24M
Editas Medicine Inc 0.2% Unchanged 8,889,000 $22.8M
Q32 Bio Inc 0.2% Unchanged 2,332,457 $19.3M
Anteris Technologies Global 0.2% Trimmed 18% 2,474,076 $19.2M
ET Electra Therapeutics Inc 0.2% New 1,692,965 $19M
Altimmune Inc 0.2% Unchanged 6,500,000 $18.6M
Benitec Biopharma Inc 0.2% Unchanged 1,850,000 $18.5M

Showing top 60 of 92 positions.

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
Freenome Inc New +15,367,270 +$242M 2.4%
Biocryst Pharmaceuticals Inc Exited −15,827,186 −$158M —
Wave Life Sciences Ltd Exited −26,975,505 −$157M —
NI Nuvalent Inc-a Exited −1,246,456 −$154M —
Amylyx Pharmaceuticals Inc New +4,279,341 +$125M 1.2%
Wave Life Sciences Inc New +26,975,505 +$99.8M 1.0%
Gh Research PLC Trimmed −4,027,806 −$94.6M 0.8%
LB Latigo Biotherapeutics Inc New +5,302,933 +$88.6M 0.9%
Obsidian Therapeutics Inc New +5,957,103 +$81.8M 0.8%
ZL Zai Lab Ltd-adr Trimmed −2,927,990 −$77.1M 0.7%

Showing the 10 largest of 53 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
Ascendis Pharma A/s New +10,281,496 +$2.74B 23.8%
AP Ascendis Pharma A/s - ADR Exited −10,281,496 −$2.35B —
PM Parabilis Medicines Inc New +28,933,371 +$792M 6.9%
Hemab Therapeutics Holdings New +7,808,627 +$287M 2.5%
Dianthus Therapeutics Inc Exited −2,611,733 −$219M —
NI Nuvalent Inc-a Trimmed −1,287,689 −$159M 1.3%
AS Abivax Sa-adr New +1,132,557 +$151M 1.3%
Oruka Therapeutics Inc New +1,554,597 +$148M 1.3%
PP Praxis Precision Medicines I Exited −373,787 −$120M —
Sarepta Therapeutics Inc Exited −3,902,596 −$84.9M —

Showing the 10 largest of 55 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
Cidara Therapeutics Inc Exited −3,365,523 −$743M —
Avidity Biosciences Inc Exited −8,641,031 −$623M —
Spyglass Pharma Inc New +8,021,117 +$208M 2.2%
ZL Zai Lab Ltd-adr New +5,707,262 +$107M 1.1%
Sarepta Therapeutics Inc New +3,902,596 +$84.9M 0.9%
Dianthus Therapeutics Inc Added +1,000,000 +$83.9M 2.3%
Arcellx Inc Exited −1,267,156 −$82.6M —
BB Belite Bio Inc - ADR Exited −432,484 −$69.2M —
NI Nuvalent Inc-a Added +654,088 +$67M 2.8%
Wave Life Sciences Ltd Added +8,772,496 +$63.6M 2.1%

Showing the 10 largest of 53 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
89bio Inc Exited −19,889,683 −$292M —
Climb Bio Inc Trimmed −20,125,439 −$138M 0.8%
Biocryst Pharmaceuticals Inc New +15,827,186 +$123M 1.3%
Arcellx Inc Trimmed −1,769,371 −$115M 0.8%
PP Praxis Precision Medicines I New +373,787 +$110M 1.1%
Rhythm Pharmaceuticals Inc Added +985,478 +$105M 7.3%
BB Belite Bio Inc - ADR Trimmed −442,516 −$70.8M 0.7%
Olema Pharmaceuticals Inc New +2,600,000 +$65M 0.7%
NI Nuvalent Inc-a Added +633,601 +$63.7M 1.9%
Evommune Inc New +3,458,770 +$59.2M 0.6%

Showing the 10 largest of 61 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
NI Nuvalent Inc-a New +1,246,456 +$108M 1.3%
Vor Biopharma Inc New +1,982,301 +$96.6M 1.2%
Dyne Therapeutics Inc Exited −9,714,392 −$92.5M —
BB Belite Bio Inc - ADR New +875,000 +$64.8M 0.8%
Vor Biopharma Inc Exited −39,646,039 −$64.2M —
Avidity Biosciences Inc Added +1,375,000 +$59.9M 4.6%
Rxsight Inc Exited −3,702,967 −$48.1M —
Mineralys Therapeutics Inc Added +1,176,470 +$44.6M 3.4%
Pepgen Inc Added +9,375,000 +$43.3M 1.1%
Tourmaline Bio Inc Exited −2,538,925 −$40.6M —

Showing the 10 largest of 36 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Cidara Therapeutics Inc Added +2,272,727 +$111M 2.8%
Apogee Therapeutics Inc Exited −1,569,491 −$58.6M —
ZL Zai Lab Ltd-adr Exited −1,295,040 −$46.8M —
DO Day One Biopharmaceuticals I Exited −5,755,577 −$45.6M —
Urogen Pharma Ltd Exited −3,206,271 −$35.5M —
Rhythm Pharmaceuticals Inc Trimmed −523,053 −$33.1M 5.9%
Taysha Gene Therapies Inc Added +12,683,145 +$29.3M 0.9%
Avidity Biosciences Inc Added +965,623 +$27.4M 3.5%
Astria Therapeutics Inc Exited −5,105,213 −$27.3M —
Kura Oncology Inc Exited −4,004,610 −$26.4M —

Showing the 10 largest of 52 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
LB Legend Biotech Corp-adr Exited −7,506,934 −$244M —
Vaxcyte Inc Added +3,499,959 +$132M 7.7%
SS SPDR S&P Biotech ETF Exited −1,228,240 −$111M —
Sionna Therapeutics Inc New +10,445,322 +$109M 1.8%
Axsome Therapeutics Inc Exited −1,000,000 −$84.6M —
VP Verona Pharma PLC - ADR Exited −1,766,830 −$82.1M —
Disc Medicine Inc New +1,577,106 +$78.3M 1.3%
PP Praxis Precision Medicines I Exited −761,955 −$58.6M —
RP Recursion Pharmaceuticals-a Exited −7,725,096 −$52.2M —
Geron Corp Added +30,369,830 +$48.3M 1.6%

Showing the 10 largest of 44 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
Biogen Inc Exited −1,184,456 −$230M —
Septerna Inc New +6,995,858 +$160M 2.1%
VP Verona Pharma PLC - ADR Trimmed −3,242,823 −$151M 1.1%
SS SPDR S&P Biotech ETF New +1,228,240 +$111M 1.5%
Arcellx Inc Added +935,848 +$71.8M 2.8%
Janux Therapeutics Inc Added +1,200,000 +$64.2M 7.4%
EH Evolent Health Inc - A Trimmed −4,937,665 −$55.5M 0.5%
AP Ascendis Pharma A/s - ADR Added +402,316 +$55.4M 18.5%
Cg Oncology Inc Exited −1,397,433 −$52.7M —
RP Recursion Pharmaceuticals-a Trimmed −7,659,519 −$51.8M 0.7%

Showing the 10 largest of 51 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support